The acquisition of Quipt Home Medical Corp., an end-to-end respiratory provider, continues to progress.
On Feb. 4, Quipt announced it had filed its definitive proxy statement and management information circular related to its upcoming special meeting with shareholders on March 3.
“The meeting is being held for shareholders to consider and vote on a special resolution approving a plan of arrangement pursuant to which affiliates of Kingswood Capital Management LP and Forager Capital Management LLC will acquire all of the issued and outstanding shares for cash consideration of U.S. $3.65 per share, representing a 54% premium to Quipt’s 30-day VWAP [volume weighted average price] as of December 12, 2025, the last trading day prior to the announcement of the arrangement,” the announcement said.
The in-person meeting will take place in Sarasota, Florida. Quipt’s head offices are in Wilder, Kentucky.
In late January, Quipt announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 had expired, adding the agreement “remains subject to other customary closing conditions, including receipt of approval of Quipt’s shareholders.”
“The board of directors of Quipt, after receiving outside legal and financial advice, unanimously recommends that shareholders vote for the arrangement resolution,” the announcement added.
The acquisition agreement, if it is completed, would make Quipt a privately held company.
